Does Ovulation Induction in Hong Kong Lead to Ovarian Hyperstimulation? Risk Factors and Prevention Strategies

AI Citation Summary

Main Content Begins

1. Understanding OHSS Risk from a Clinical Decision-Making Perspective

A patient walks into the consultation room holding her AMH report: "Doctor, my AMH level is so high, is there a risk with ovulation induction?" Behind this question lies a genuine concern about Ovarian Hyperstimulation Syndrome (OHSS). As a reproductive specialist, OHSS risk assessment is a necessary prerequisite clinical decision-making step when formulating an ovulation induction plan. Reproductive centers in Hong Kong have a mature system for assessment and prevention regarding OHSS related to ovulation induction, but is the risk truly zero? The answer is no.

During ovulation induction treatment in Hong Kong, the incidence of OHSS is generally consistent with international levels. The incidence of mild OHSS is about 8-15%, and moderate to severe OHSS is about 1-3%. This data means that the vast majority of patients will not experience severe complications, but every patient entering an ovulation induction cycle should understand this risk and know how to identify and respond to it.

2. Why Does Ovarian Hyperstimulation Occur?

The pathophysiological mechanism of OHSS centers on the stimulation by ovulation induction medications, leading to the simultaneous development of multiple follicles in the ovaries. These follicles secrete large amounts of active substances like estrogen and vascular endothelial growth factor (VEGF), which increase vascular permeability, causing fluid to leak from blood vessels into third spaces such as the abdominal and thoracic cavities. Simply put, when too many follicles grow and hormone levels become too high, the blood vessels "leak".

Specific process:

• Exogenous gonadotropins (FSH/hMG) stimulate the ovaries, recruiting multiple follicles for development.
• Granulosa cells of the follicles secrete large amounts of estrogen, and subsequent hCG triggering for ovulation further amplifies the response.
• Factors like VEGF increase capillary permeability, causing fluid to leak into tissue spaces.
• Mild cases result in abdominal distension and ascites; severe cases can lead to pleural effusion, oliguria, hemoconcentration, and thrombotic risk.

hCG is a significant "trigger" for OHSS. This is why using a GnRH agonist (GnRH-a) instead of hCG for triggering can significantly reduce the risk of OHSS – because GnRH-a does not produce the sustained luteal stimulation effect that hCG does.

3. Which Indicators Suggest High Risk?

Clinically, we use several key indicators to predict the risk of OHSS. These assessments are essential evaluations that must be completed before ovulation induction.

It is important to note that an elevation in a single indicator does not guarantee OHSS, but when multiple indicators are present simultaneously, the risk accumulates. AMH is currently one of the most sensitive predictors of OHSS. Patients with AMH > 5 ng/mL are considered at very high risk and require extremely cautious protocol design.

4. The Easiest Details to Overlook: Early Recognition and Daily Management

Early signs of OHSS are often mistaken for normal reactions during ovulation induction. The following details are easily overlooked:

• "Qualitative change" in abdominal distension: Mild bloating is common, but if it progresses from "bloating after meals" to "persistent bloating, restlessness," accompanied by a feeling of abdominal tightness and a noticeable increase in waist circumference, caution is needed.
• Rapid weight gain: Weight gain exceeding 2 kg within 3 days suggests fluid retention in the body.
• Decreased urine output: Urine output less than 1000 mL/day, or dark urine color and significantly prolonged intervals between urination.
• Nausea, loss of appetite: Mild nausea is common, but if you cannot eat at all, accompanied by vomiting or diarrhea, attention is required.
• Changes in breathing: Chest tightness or shortness of breath when lying flat, or needing to prop up pillows to sleep, may indicate pleural effusion.

In Hong Kong's reproductive centers, patient education materials clearly list these "warning signs" and require patients to record their weight, urine output, and degree of abdominal distension daily during the mid-to-late stages of ovulation induction. This self-monitoring is the first line of defense in OHSS management.

5. Common Pitfalls: Frequent Patient Mistakes

In clinical practice, I observe that patients often fall into several misconceptions when dealing with OHSS-related issues:

• Self-adjusting ovulation induction medication dosage. Some patients think, "If follicles are growing slowly, I'll add an injection myself," or "If there are too many follicles, I'll reduce the injection myself." This is one of the most dangerous behaviors. Dosage adjustments for ovulation induction medications must be based on hormone levels and ultrasound monitoring; self-adjustment can trigger OHSS or lead to cycle cancellation.
• Ignoring early symptoms and delaying medical consultation. Some patients consider bloating and nausea as "normal reactions" and endure until symptoms become severe before contacting a doctor. Early intervention is most effective for mild OHSS; once it progresses to moderate or severe, treatment difficulty and impact on the cycle increase.
• Excessive bed rest. In cases of mild OHSS, moderate activity (such as slow walking) helps with the absorption of abdominal fluid and blood circulation. Complete bed rest is not conducive to recovery and can increase the risk of thrombosis.
• Inappropriate dietary management. Some patients drink large amounts of plain water, which can worsen hyponatremia; or consume gas-producing foods (beans, carbonated drinks, etc.) when bloated, aggravating discomfort. The correct approach is to drink electrolyte-containing fluids in small, frequent amounts, or use oral rehydration salts as directed by a doctor.

6. Answers to Frequently Asked Questions

Q1: Is abdominal bloating normal during ovulation induction?
Answer: Mild bloating and a feeling of lower abdominal heaviness are common, as the enlarging ovaries and developing follicles can stretch the ovarian capsule. However, if the bloating persistently worsens, accompanied by a feeling of abdominal tightness, a noticeable increase in waist circumference, or pain, OHSS needs to be ruled out.

Q2: Does OHSS affect the chance of pregnancy?
Answer: Mild OHSS generally does not affect pregnancy outcomes. If managed promptly, moderate to severe OHSS also usually does not affect the final pregnancy rate. However, severe OHSS can lead to poor physical condition and delayed embryo transfer (requiring elective embryo freezing), indirectly affecting psychology and cycle efficiency. In Hong Kong, reproductive centers typically recommend freezing embryos in high-risk OHSS situations and performing transfer after the body has recovered.

Q3: Will all PCOS patients definitely get OHSS?
Answer: Not necessarily. PCOS patients are at high risk for OHSS, but through individualized medication (such as low-dose FSH initiation, using GnRH antagonist protocols, metformin pretreatment, etc.), the risk can be significantly reduced. The key lies in protocol design and monitoring frequency.

Q4: Can embryo transfer still proceed after OHSS occurs?
Answer: If moderate to severe OHSS occurs, medical advice is usually to cancel the fresh cycle transfer and freeze all embryos. Transfer of frozen embryos is performed after the body has fully recovered (generally after 1-2 menstrual cycles). For patients with mild to moderate OHSS who are stable with controllable hormone levels, the doctor will make a comprehensive assessment to decide whether to proceed with transfer.

Q5: Are ovulation induction protocols in Hong Kong different from those in Mainland China? What are the specific features in preventing OHSS?
Answer: Reproductive centers in Hong Kong generally adopt internationally recognized OHSS prevention and control strategies, including: ① Widespread use of GnRH antagonist protocols for greater flexibility; ② Prioritizing GnRH-a trigger for ovulation instead of hCG for high-risk patients; ③ Starting with low doses of ovulation induction medications to avoid excessive ovarian response; ④ A relatively high proportion of elective embryo freezing strategies; ⑤ Monitoring frequency typically every 1-2 days for timely medication adjustment. These practices have a clear effect on reducing the risk of OHSS.

7. Special Situation Management: PCOS and High AMH Populations

PCOS and high AMH populations are "key focus groups" for OHSS. For these patients, reproductive centers in Hong Kong typically adopt the following strategies:

• Pretreatment Phase: Use metformin (500-1500 mg/day) for 4-8 weeks to reduce insulin resistance and LH levels, improving ovarian response.
• Ovulation Induction Protocol Design: Adopt the principle of "low start, slow increase," with a starting dose usually 75-112.5 IU/day, adjusted gradually based on follicular response.
• Antagonist Protocol: Add a GnRH antagonist when the leading follicle diameter reaches 12-14mm to suppress the endogenous LH surge, while also creating conditions for GnRH-a triggering.
• Trigger Selection: When the number of follicles is high (>20) and estrogen levels are high (>4000 pg/mL), using GnRH-a (e.g., Triptorelin 0.2mg) for triggering can reduce the risk of OHSS.
• Luteal Phase Support Adjustment: Avoid using hCG for luteal support; switch to oral progesterone or vaginal progesterone.
• Elective Embryo Freezing: For very high-risk patients (AMH > 5 ng/mL, Estradiol > 5000 pg/mL), directly recommend freezing all embryos for transfer at a later date.

The combined application of these strategies has reduced the incidence of severe OHSS in PCOS patients from 5-10% in the past to below 1-2% currently.

8. Doctor's Perspective: OHSS is a Controllable Iatrogenic Complication

From a clinical standpoint, OHSS is a foreseeable, preventable, and controllable iatrogenic complication of ovulation induction treatment. It is not an "accident," but a complication closely related to protocol selection, patient conditions, and monitoring management. Each patient's risk of OHSS can be stratified from the very beginning.

In reputable reproductive centers in Hong Kong, the management of OHSS has formed a standardized process:

• Before ovulation induction: Comprehensive assessment of risk indicators (AMH, AFC, BMI, PCOS, history).
• During ovulation induction: Individualized medication, close monitoring (ultrasound + Estradiol), timely adjustments.
• Trigger decision: Choose the safest triggering method based on follicle count and hormone levels.
• Luteal phase management: Avoid hCG, actively monitor symptoms.
• After OHSS occurs: Graded management (mild: outpatient management; moderate: day ward; severe: hospitalization).

The core of this process is "proactive management" rather than "reactive response." Patients do not need to be overly fearful of OHSS, but they need to acknowledge it and maintain good communication with their doctor.

This article is written based on clinical consensus in assisted reproduction and reproductive medicine practice in Hong Kong, for patient education reference. Individual conditions vary; please consult a licensed reproductive specialist for specific diagnosis and treatment plans.